



**Supplemental Figure 1.** Dose-dependent changes in cortical actin arrays are elicited by elf26 treatment.

**(A)** Actin filament density was enhanced in a dose-dependent fashion. Hypocotyls were treated with elf26 peptide at various concentrations for 5 min, and actin filament abundance was measured in epidermal cells from the base of the hypocotyl. Cells treated with 0.1 or 1 μM elf26 had significantly increased actin filament density. **(B)** The extent of actin filament bundling was not significantly different from mock for any treatment investigated. The same images analyzed in **(A)** were measured for actin filament bundling. **(C)** Actin filament density in epidermal cells from the base of the hypocotyl, treated with 0.1 or 1 μM elf26, was significantly increased 15 min after treatment compared to mock control. **(D)** The extent of actin filament bundling was only elevated after 15 min of treatment with 1 μM elf26 peptide, compared to mock. Treatment with flg22 peptide did not elicit any measurable changes to either actin architecture parameter at any concentration tested. Values given are means ± SEM ( $n = 300$  cells per concentration and treatment from at least 30 hypocotyls). Asterisks represent significant differences by ANOVA, with Tukey HSD post-hoc analysis (nd = not significantly different from mock; \*\*\* =  $P < 0.001$ ).




**Supplemental Figure 2.** *FLAGELLIN SENSING2* is not expressed in dark-grown *Arabidopsis* seedlings.

Real-time quantitative PCR (RT-qPCR) analyses of gene transcripts in wild-type (WT) and several *Arabidopsis* knockout mutants, *fls2 efr-1*, and *adf4*. Expression was confirmed by RT-qPCR on 5-days-after-germination, dark-grown seedlings. *FLS2* expression was absent in the *fls2* knockout mutant, as well as all other genotypes grown in the dark. Additionally, *EFR* transcripts were absent in the *efr-1* knockout mutant. Expression of *FRK1* and the housekeeping gene, glyceraldehyde-3-phosphate dehydrogenase (*GAPD*), was absent from controls lacking reverse transcriptase (not shown). Mean values from triplicate biological samples and technical replications are plotted  $\pm$  SD, normalized to *GAPD* expression. (au, arbitrary units)




**Supplemental Figure 3.** A 35S:*ADF4*;*adf4* rescue line responds to elf26 treatment.

(A) Actin filament abundance, or percent occupancy, was measured at the base of 5 days-after-germination hypocotyls. Epidermal cells from WT and the rescue line responded to treatment with 1 μM elf26 or 1 μM chitin, whereas the *adf4* mutant did not respond to elf26 treatment but did respond to chitin. (B) The extent of actin filament bundling was measured from the same images used in (A). There was no significant difference between treatments with flg22, elf26, or mock. Values given are means ± SEM (n = 100 cells per treatment, from at least 25 hypocotyls). Asterisks represent significant differences by ANOVA, with Tukey HSD post-hoc analysis ( $P < 0.001$ ; nd = not significantly different from mock).



**Supplemental Figure 4.** The homozygous *adf1* mutant is a knockout line.

Quantitative real-time PCR (qRT-PCR) analysis of *ADF* transcripts in wild-type, and *adf1* homozygous mutant lines. Expression of *ADF1* and *ADF4* transcripts was confirmed by qRT-PCR on 5 DAG etiolated WT seedlings. *ADF1* was absent from the *adf1* knockout mutant, whereas *ADF4* is expressed at WT levels. Expression was normalized to the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (*GAPD*) and transcripts were not detected in controls lacking reverse-transcriptase (not shown). Quadruple biological and triplicate technical replications are plotted  $\pm$  SEM.



**Supplemental Figure 5.** The *adf1* mutant fails to respond to elf26 or chitin treatment.

(A, C) Quantitative values for actin filament density were measured following treatment with mock, 1  $\mu$ M elf26 or 1  $\mu$ M chitin. Epidermal cells from WT hypocotyls responded to elf26 or chitin treatment with an increase in actin filament abundance (A, C). An increase in actin filament density occurred following chitin treatment of the *adf4* mutant; however, there was no change to filament abundance following treatment with elf26 (A). In contrast, the *adf1* mutant did not respond with an increase in filament abundance following treatment with either MAMP (C). (B, D) The extent of actin filament bundling was measured in the *adf4* (B) and *adf1* mutants (D); however, there were no significant differences among treatments with mock, elf26 or chitin. Images of epidermal cells located at the base of 5 DAG hypocotyls were obtained from either *adf4* or *adf1* homozygous mutants or their WT siblings. Values given are means  $\pm$  SEM ( $n = 200$  cells from 10 hypocotyls per treatment and genotype). Asterisks represent significant differences by ANOVA, with Tukey HSD post-hoc analysis ( $P < 0.001$ ; nd = not significantly different from mock).

**Supplemental Table 1. Actin-dynamics parameters from mock and elf26-treated *adf4* hypocotyl epidermal cells**

Stochastic Dynamics Parameters		WT + Mock	WT + 1 $\mu$ M elf26	<i>adf4</i> + Mock	<i>adf4</i> + 1 $\mu$ M elf26
Elongation rate; $\mu\text{m s}^{-1}$		1.7 $\pm$ 0.1 <sup>‡</sup>	1.8 $\pm$ 0.1 <sup>nd</sup>	1.7 $\pm$ 0.1 <sup>nd</sup>	1.8 $\pm$ 0.1 <sup>nd,nd</sup>
Severing frequency; breaks $\mu\text{m}^{-1}\text{s}^{-1}$		0.015 $\pm$ 0.002	0.009 $\pm$ 0.001 <sup>c</sup>	0.007 $\pm$ 0.001 <sup>c</sup>	0.005 $\pm$ 0.001 <sup>c,nd</sup>
Max. filament length; $\mu\text{m}$		13.6 $\pm$ 0.6	18.4 $\pm$ 0.6 <sup>c</sup>	17.4 $\pm$ 0.7 <sup>c</sup>	19.1 $\pm$ 0.6 <sup>c,nd</sup>
Max. filament lifetime; s		20 $\pm$ 1	26 $\pm$ 1 <sup>c</sup>	25 $\pm$ 1 <sup>b</sup>	26 $\pm$ 2 <sup>c,nd</sup>
Re-growth of severed ends; %		2.5 $\pm$ 0.4	2.5 $\pm$ 0.5 <sup>nd</sup>	2.6 $\pm$ 0.5 <sup>nd</sup>	2.6 $\pm$ 0.5 <sup>nd,nd</sup>
Annealing of severed ends; %		2.2 $\pm$ 0.5	8.9 $\pm$ 0.9 <sup>c</sup>	5.3 $\pm$ 0.9 <sup>a</sup>	8.8 $\pm$ 0.9 <sup>c,d</sup>
Filament origin; % per cell:	<i>de novo</i>	34.3 $\pm$ 0.4	28.7 $\pm$ 0.4 <sup>b</sup>	32.0 $\pm$ 0.4 <sup>nd</sup>	23.0 $\pm$ 0.4 <sup>c,e</sup>
	ends	21.0 $\pm$ 0.3	20.3 $\pm$ 0.4 <sup>nd</sup>	21.7 $\pm$ 0.4 <sup>nd</sup>	19.7 $\pm$ 0.3 <sup>nd,nd</sup>
	side	44.7 $\pm$ 0.4	50.7 $\pm$ 0.4 <sup>a</sup>	46.3 $\pm$ 0.5 <sup>nd</sup>	57.3 $\pm$ 0.6 <sup>c,e</sup>

<sup>‡</sup> Values given are means  $\pm$  SEM, with  $n > 50$  filaments from  $n > 30$  epidermal cells and at least 10 hypocotyls per line.

<sup>nd</sup> Not significantly different from mock control value by Student's *t* test; *P*-value  $> 0.05$ .

<sup>a</sup> Significantly different from WT + mock control value by Student's *t*-test; *P*-value  $\leq 0.05$ .

<sup>b</sup> Significantly different from WT + mock control value by Student's *t*-test; *P*-value  $\leq 0.01$ .

<sup>c</sup> Significantly different from WT + mock control value by Student's *t*-test; *P*-value  $\leq 0.001$ .

<sup>d</sup> Significantly different from *adf4* + mock control value by Student's *t*-test; *P*-value  $\leq 0.05$ .

<sup>e</sup> Significantly different from *adf4* + mock control value by Student's *t*-test; *P*-value  $\leq 0.001$ .

**Supplemental Table 2. Gene-specific primers used for real-time quantitative PCR**

Gene	Forward Primer	Reverse primer
<i>GAPD</i>	5'-CACTTGAAGGGTGGTGCCAAG-3'	5'-CCTGTTGTCCGCAACGAAGTC-3'
<i>FLS2</i>	5'-TTGTCCACGTAAGATGTTCCAG-3'	5'-TTGCAGCGAAGTCACATATTG-3'
<i>EFR</i>	5'-TGGAATAACTCGTCCAGTGG-3'	5'-CAGATGGGTTACCATCACTGG-3'
<i>FRK1</i>	5'-GGGTCAGATTTCAACAGTTGTC-3'	5'-AATAGCAGGTTGGCCTGTAATC-3'
<i>WRKY33</i>	5'-GTGATATTGACATTCTTGACGA-3'	5'-GATGGTTGTGCACTTGTAGTA-3'
<i>PHI1</i>	5'-TTGGTTTAGACGGGATGGTG-3'	5'-ACTCCAGTACAAGCCGATCC-3'
<i>NHL10</i>	5'-TTCCTGTCCGTAACCCAAAC-3'	5'-CCCTCGTAGTAGGCATGAGC-3'
<i>CYP81F2</i>	5'-AAATGGAGAGAGCAACACAATG-3'	5'-ATCGCCATTCCAATGTTAC-3'